Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02656862
Other study ID # RESFANDI
Secondary ID
Status Completed
Phase N/A
First received January 5, 2016
Last updated March 7, 2017
Start date October 2015
Est. completion date December 31, 2016

Study information

Verified date March 2017
Source Institute of Tropical Medicine, Belgium
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Fever is one of the main reasons for outpatient consultations in sub-saharan Africa. Following the introduction of malaria RDTs, clinicians face a high number of malaria-negative patients for whom they do not have a clear diagnosis. Through clinical history and examination, acute fever patients are categorized into: acute respiratory infections, urinary tract infections and other focal infections, diarrheal fevers and undifferentiated fevers. The latter being patients where no focal source of infections can be found during the consultation visit. In this proposal, the investigators focus on these acute undifferentiated fevers in an outpatient clinic.

These fevers have the challenge of few point-of-care tests (POCT) available for the clinicians to identify the etiology of fever and guide treatment in resource-limited countries. As a consequence, over-prescription of antibiotics has increased. In order to improve patient outcomes while supporting judicious use of antimicrobials, there is an urgent need to change the management of febrile patients in low-income countries. This can only be achieved by providing evidence-based clinical guidelines for the management of these acute febrile patients. To develop such guidelines, epidemiological data on etiologies of undifferentiated fever need to be generated. The investigators will evaluate pathogen infection (such as dengue, chikungunya and others) in 640 patients ≥ 2 years old with acute undifferentiated fever. To evaluate the existence of aspecific and subclinical infections and co-infections, the investigators will also test a subsample of 200 patients with ARI, UTI, diarrheal fever and malaria. The investigators expect to have as main results: proportions of each syndrome among fever patients, key pathogens associated with undifferentiated fever and their clinical presentation and demographic characteristics.


Recruitment information / eligibility

Status Completed
Enrollment 301
Est. completion date December 31, 2016
Est. primary completion date December 31, 2016
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria:

- at least 2 years old

- a history of acute fever (i.e. = 2 days and = 7 days)

- an axillary temperature of =37.5°C

- written informed consent obtained;

Exclusion Criteria:

- main complaint for consultation is an injury, trauma or poisoning

- hospitalization or delivery in the preceding 2 weeks

- suspicion of meningitis/encephalitis

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention


Locations

Country Name City State
Congo, The Democratic Republic of the Lisungi Health Center Kinshasa

Sponsors (4)

Lead Sponsor Collaborator
Institute of Tropical Medicine, Belgium Institut National de recherche Biomédicale (INRB), Kinshasa, DRC, Université de Kinshasa, DRC, Universiteit Antwerpen

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of key pathogens among study participants with 'undifferentiated fever' The key pathogens will be identified through specific laboratory diagnostic tests on the blood/serum of included patients. At consultation over a period of 6 months